Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Endourology|September 30, 2005
Long-term outcome of hand-assisted laparoscopic radical nephrectomy for localized stage T1/T2 renal-cell carcinomaMasahiko Harano, Masatoshi Eto, Kazuya Omoto, et al.
Cancer Research|November 4, 2005
Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in miceMasahiko Harano, Masatoshi Eto, Toshiro Iwai, et al.
Cancer Research|June 4, 2009
Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumorYoriyuki Kamiryo, Masatoshi Eto, Hisakata Yamada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host diseaseMasatoshi Eto, Masahiko Harano, Katsunori Tatsugami, et al.
Cancer Science|November 29, 2008
Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantationMasumitsu Hamaguchi, Masatoshi Eto, Yoriyuki Kamiryo, et al.
Anticancer Research|August 2, 2019
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional StudyMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Medical Oncology (Northwood, London, England)|March 1, 2019
Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional studyMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Anticancer Research|January 2, 2020
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After DocetaxelMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2019
Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional studyMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Anti-Cancer Drugs|January 9, 2020
Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional studyMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Pageof 3